Literature DB >> 26803325

Are normal-sized ascending aortas at risk of late aortic events after aortic valve replacement for bicuspid aortic valve disease?

Kushtrim Disha1, Mina Rouman2, Maria-Anna Secknus3, Thomas Kuntze2, Evaldas Girdauskas2.   

Abstract

OBJECTIVES: Bicuspid aortic valve (BAV)-associated aortopathy has been proposed to progress after isolated aortic valve replacement (AVR) surgery, which has been traditionally used as an argument against a TAVR procedure in this clinical subset. Still, more than half of BAV patients have a normal-sized proximal aorta at the time of AVR surgery. We aimed to analyse the long-term risk of adverse aortic events after isolated conventional AVR surgery for BAV and normal-sized proximal aorta.
METHODS: A total of 200 consecutive patients (mean age 56 ± 13 years, 73% men) with BAV disease and ascending aortic diameter of <40 mm underwent isolated conventional AVR from 1995 through 2008 and were identified from our institutional BAV database. Long-term follow-up data (a total of 1532 patient-years) were obtained for all hospital survivors. Composite adverse aortic/cardiovascular events were defined as the need for redo aortic surgery, the occurrence of aortic dissection/rupture, or sudden cardiac death during follow-up.
RESULTS: A total of 25 (13%) patients died after a mean follow-up of 8.5 ± 5 years post-AVR surgery, which resulted in an overall survival rate of 75 ± 6 and 87 ± 7% at 15 years postoperatively, for BAV-aortic stenosis and BAV-aortic regurgitation, respectively (P = 0.6). An adverse aortic event occurred in 1 (0.5%) study patient, while 5 (2.5%) further patients suffered sudden cardiac death. Only 1 patient required redo aortic surgery. No documented aortic dissection/rupture occurred. Redo AVR surgery due to endocarditis or structural valve degeneration was performed in 6 (3%) patients. The rate of freedom from composite adverse events was 92 ± 5 and 95 ± 4% at 15 years, for the AS and AR subgroups, respectively (P = 0.7).
CONCLUSIONS: BAV patients with aortic valve dysfunction and normal-sized ascending aorta are at considerably low risk of late adverse aortic events after isolated AVR.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Aortic event; Aortic valve replacement; Ascending aorta; Bicuspid aortic valve

Mesh:

Year:  2016        PMID: 26803325     DOI: 10.1093/icvts/ivv387

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

Review 1.  Bicuspid aortic valve and aortic coarctation in congenital heart disease-important aspects for treatment with focus on aortic vasculopathy.

Authors:  Christoph Sinning; Elvin Zengin; Rainer Kozlik-Feldmann; Stefan Blankenberg; Carsten Rickers; Yskert von Kodolitsch; Evaldas Girdauskas
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

2.  Should the dilated ascending aorta be repaired at the time of bicuspid aortic valve replacement?

Authors:  Tsuyoshi Kaneko; Prem Shekar; Vladimir Ivkovic; Nicholas T Longford; Chuan-Chin Huang; Martin I Sigurdsson; Robert C Neely; Maroun Yammine; Julius I Ejiofor; Vanessa Montiero Vieira; Jasmine T Shahram; Karam M Habchi; Gregory W Malzberg; Peter S Martin; Jordan Bloom; Eric M Isselbacher; J Daniel Muehlschlegel; Thoralf M Sundt; Simon C Body
Journal:  Eur J Cardiothorac Surg       Date:  2018-03-01       Impact factor: 4.191

3.  Biscuspid aortic valve syndrome: diversity and controversy.

Authors:  María Martín; Vicente Barriales; Guillermo Solache-Berrocal; José Rozado; César Morís; Isabel Rodríguez
Journal:  Int J Cardiovasc Imaging       Date:  2016-02-11       Impact factor: 2.357

4.  Con: "Debate: does every ascending aorta repair require at least an open distal anastomosis at the innominate? Or not?"

Authors:  Kenji Minatoya
Journal:  J Vis Surg       Date:  2018-03-13

5.  Importance of bicuspid aortic valve phenotype on aortopathy.

Authors:  Evaldas Girdauskas; John A Elefteriades
Journal:  Ann Cardiothorac Surg       Date:  2022-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.